Vall d'Hebron-Cemcat researchers participate in the revision of the McDonald diagnostic criteria for multiple sclerosis

The meeting, held between November 29 and December 2 in Barcelona, brought together experts and opinion leaders in the field of multiple sclerosis from around the world. The McDonald criteria are the clinical criteria used to diagnose multiple sclerosis. Established in 2001, by an international panel of experts in the disease led by Ian McDonald, they have been modified in revisions in 2005, 2010 and 2017, with the aim of facilitating their use in clinical practice, shortening the time to diagnosis and initiation of treatment and improving case detection.

Dr. Xavier Montalban receives the ICS Hospitals Research Career Award 2023

Xavier Montalban, Director of the Multiple Sclerosis Center of Catalonia (Cemcat), Head of the Neurology Service of the Vall d'Hebron University Hospital and of the Clinical Neuroimmunology research group of the Vall d'Hebron Research Institute, as well as Vice-President of the Multiple Sclerosis Foundation, has been awarded for his significant contribution to the development of research within the Catalan Institute of Health.

A single dose of attenuated vaccines could protect multiple sclerosis patients before starting immunosuppressive therapy

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment. The study was carried out by René Carvajal, Mar Tintoré and Susana Otero-Romero, researchers at Cemcat, led by Xavier Montalbán, and the Vall d'Hebron University Hospital.